CareDx, Inc (NASDAQ:CDNA) has been given an average rating of “Buy” by the eight brokerages that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $79.80.
Several analysts have recently issued reports on the stock. Piper Sandler upped their target price on shares of CareDx from $93.00 to $100.00 and gave the stock an “overweight” rating in a research note on Thursday, May 6th. TheStreet upgraded shares of CareDx from a “d” rating to a “c-” rating in a research report on Friday, March 19th. Raymond James reduced their price target on shares of CareDx from $98.00 to $90.00 and set a “strong-buy” rating for the company in a research report on Wednesday. Zacks Investment Research upgraded shares of CareDx from a “sell” rating to a “hold” rating in a research report on Tuesday, April 27th. Finally, HC Wainwright lowered shares of CareDx from a “buy” rating to a “neutral” rating in a research report on Friday, February 26th.
In other CareDx news, insider Reginald Seeto sold 10,704 shares of the stock in a transaction dated Monday, March 1st. The shares were sold at an average price of $85.45, for a total transaction of $914,656.80. Also, insider Peter Maag sold 10,000 shares of the stock in a transaction dated Friday, March 5th. The stock was sold at an average price of $61.29, for a total transaction of $612,900.00. The disclosure for this sale can be found here. Insiders have sold 60,704 shares of company stock valued at $4,517,557 in the last quarter. Company insiders own 3.10% of the company’s stock.
Shares of NASDAQ CDNA traded down $2.27 during trading on Friday, hitting $63.48. The stock had a trading volume of 4,764 shares, compared to its average volume of 734,300. CareDx has a 12 month low of $26.61 and a 12 month high of $99.83. The company has a market capitalization of $3.30 billion, a PE ratio of -142.93 and a beta of 0.84. The firm has a fifty day moving average of $72.66 and a two-hundred day moving average of $71.50.
CareDx (NASDAQ:CDNA) last posted its earnings results on Wednesday, May 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.13. CareDx had a negative net margin of 11.79% and a negative return on equity of 10.95%. On average, research analysts predict that CareDx will post -0.47 earnings per share for the current year.
CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.